Lionel Spielmann

Dr. Lionel Spielmann

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
LSLionel Spielmann
Lionel Spielmann
BNBenoit Nespola
Benoit Nespola
FSFrançois Séverac
François Séverac
EAEmmanuel Andres
Emmanuel Andres
RKRomain Kessler
Romain Kessler
AMAlain Meyer
Alain Meyer
Objective To refine the spectrum of anti-Ku-associated disease, a condition that is equivocally described by current diagnostic criteria for connective tissue diseases. Methods Among 42 consecutive patients harbouring anti-Ku antibodies, subgroups with similar phenotypes and prognosis were delineated without an a priori diagnosis using hierarchical clustering analysis of the cumulative clinico-biological features recorded during the follow-up. Features present at baseline that most efficiently predicted the outcomes were then identified using a sensitivity–specificity sum maximisation approach. Results Clinico-biological features were clustered into three groups. Glomerulonephritis and ILD, the two fatal complications in this cohort, were unequally distributed between the three clusters that additionally differed on six clinico-biological features. Among features present at baseline, elevated serum level of creatine kinase (CK) and anti-dsDNA antibodies were generally mutually exclusive and most efficiently predicted the cluster belonging at last follow-up. Anti-Ku patients with elevated CK had a 22-fold higher risk of ILD while anti-Ku patients with anti-dsDNA antibodies had a 13-fold higher risk of glomerulonephritis Conclusion “Anti-Ku with elevated CK” syndrome and “anti-Ku with anti-dsDNA” syndrome represent two distinct entities that are important to recognise in order to best tailor patient care.

1 September 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
PDPierre-Marie Duret
Pierre-Marie Duret
ESEden Sebbag
Eden Sebbag
AMAuriane Mallick
Auriane Mallick
SGSimon Gravier
Simon Gravier
LSLionel Spielmann
Lionel Spielmann
LMLaurent Messer
Laurent Messer

1 July 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
LSLionel Spielmann
Lionel Spielmann
FSFrançois Séverac
François Séverac
AMAlain Meyer
Alain Meyer

1 March 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
LSLionel Spielmann
Lionel Spielmann
BNBenoit Nespola
Benoit Nespola
AMAlain Meyer
Alain Meyer
Table 1 Myositis-specific and associated autoantibodies in our 15 patients with anti-Ku autoantibodies and elevated CK MSA and MAA Anti-Ku patients with elevated CK n=15 Anti-Jo1 0/15 Anti-PL7 0/13 Anti-PL12 0/13 Anti-OJ 0/9 Anti-EJ 0/9 Anti-Ha 0/9 Anti-Zo 0/9 Anti-KS 0/9 Anti-U1-RNP 0/15 Anti-PM/Scl 1/14 Anti-Mi2 0/12 Anti-MDA5 1/9 Anti-TIF1γ 2/9 Anti-NXP2 0/9 Anti-SAE 0/9 Anti-SRP 0/11 Anti-HMGCR 0/9 Total 2* *One patient was positive for both anti-MDA5 and anti-TIF1γ; another had anti-PM/scl and anti-TIF1γ. CK, creatine kinase; MAA, myositis-associated autoantibodies; MSA, myositis-specific autoantibodies.